Eledon Pharmaceuticals
ELDN
27 hedge funds and large institutions have $76.8M invested in Eledon Pharmaceuticals in 2014 Q3 according to their latest regulatory filings, with 27 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
22.89% more ownership
Funds ownership: 0% → 22.89% (+23%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
+$18.9M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$10.1M |
| 3 |
TCP
Tourbillon Capital Partners
New York
|
+$8.42M |
| 4 |
RG
Redmile Group
San Francisco,
California
|
+$7.27M |
| 5 |
Franklin Resources
San Mateo,
California
|
+$7.02M |
Top Sellers
ELDN Hedge Fund Activity: Q3 2014 in Review
27 of the 3,455 institutional investors tracked by Wall St. Rank reported a position in Eledon Pharmaceuticals (ELDN) for Q3 2014, worth a combined $76.8M.
Buyers outnumbered sellers: 27 funds opened new ELDN positions and 0 closed out — a net gain of 27 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Novo Holdings A/S, opening a new position worth an estimated $18.9M.
- 27 institutional investors held Eledon Pharmaceuticals (ELDN) as of Q3 2014, up from 0 in Q2 2014.
- Funds reported $76.8M of Eledon Pharmaceuticals stock for Q3 2014.
- 27 funds opened new Eledon Pharmaceuticals positions in Q3 2014 and 0 closed out, a net change of +27 holders.
- The largest Eledon Pharmaceuticals buyer in Q3 2014 was Novo Holdings A/S, an estimated $18.9M added.
Based on aggregated 13F filings for Q3 2014.